MEA Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 CELL SOURCE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET APPLICATION COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 52
5 MIDDLE EAST & AFRICA MEDICAL CARTS MARKET: REGULATIONS 54
5.1 REGULATION IN U.S. 54
5.2 REGULATION IN CANADA 55
5.3 REGULATION IN EUROPE 55
5.4 REGULATION IN INDIA 55
5.5 REGUALTION IN JAPAN 56

6 MARKET OVERVIEW 58
6.1 DRIVERS 60
6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS 60
6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS 60
6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES 61
6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY 63
6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT 64
6.2 RESTRAINT 65
6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS 65
6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 65
6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS 66
6.3 OPPORTUNITIES 66
6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS 66
6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE 67
6.3.3 SURGE IN HEALTHCARE EXPENDITURE 67
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 68
6.4 CHALLENGES 69
6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE 69
6.4.2 LACK OF SKILLED PROFESSIONALS 69
6.4.3 STRINGENT REGULATORY FRAMEWORK 69
7 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 71
7.1 IMPACT ON PRICE 71
7.2 IMPACT ON DEMAND 71
7.3 IMPACT ON SUPPLY CHAIN 72
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 72
7.5 CONCLUSION 73
8 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE 74
8.1 OVERVIEW 75
8.2 SKIN CELLS 77
8.2.1 FIBROBLAST 78
8.2.2 KERATINOCYTES 78
8.2.3 ADIPOSE DERIVED STEM CELLS 79
8.2.4 HEPATOCYTES 79
8.2.5 MELANOCYTES 79
8.2.6 NEURAL STEM CELLS 79
8.2.7 OTHERS 79
8.3 BLOOD CELLS 79
8.3.1 PERIPHERAL BLOOD 80
8.3.2 CORD BLOOD ENDOTHELIAL CELLS 80
8.3.3 CORD BLOOD STEM CELLS 80
8.3.4 OTHERS 80
9 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE 81
9.1 OVERVIEW 82
9.2 HUMAN IPSCS 85
9.3 MOUSE IPSCS 85
10 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT 87
10.1 OVERVIEW 88
10.2 CONSUMABLES & KITS 91
10.2.1 REPROGRAMMING KITS 92
10.2.2 MEDIA 92
10.2.3 TRANSFECTION KITS 92
10.2.4 CELL IDENTIFICATION KITS 92
10.2.5 ACCESSORIES 92
10.2.6 OTHERS 92
10.3 SERVICES 92
10.4 INSTRUMENTS 93
10.4.1 IMAGING SYSTEMS 94
10.4.2 ELECTROPORATION DEVICE 94
10.4.3 INCUBATORS 94
10.4.4 OTHERS 94
11 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION 95
11.1 OVERVIEW 96
11.2 DRUG DISCOVERY AND DEVELOPMENT 99
11.3 ACADEMIC RESEARCH 99
11.4 DISEASE MODELLING 100
11.5 CELLULAR THERAPY 101
11.6 REGENERATIVE MEDICINE 101
11.7 TOXICOLOGY SCREENING 102
11.8 STEM CELL BANKING 103
11.9 3D BIOPRINTING 103
11.10 OTHERS 104
12 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER 105
12.1 OVERVIEW 106
12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 109
12.3 RESEARCH LABORATORIES 109
12.4 DIAGNOSTIC LABORATORIES 110
12.5 OTHERS 111
13 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL 112
13.1 OVERVIEW 113
13.2 DIRECT TENDER 115
13.3 RETAIL SALES 116
14 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION 117
14.1 MIDDLE EAST AND AFRICA 118
14.1.1 SOUTH AFRICA 125
14.1.2 SAUDI ARABIA 128
14.1.3 UAE 131
14.1.4 EGYPT 134
14.1.5 ISRAEL 137
14.1.6 REST OF MIDDLE EAST AND AFRICA 140
15 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE 141
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 141
16 SWOT ANALYSIS 142

17 COMPANY PROFILE 143
17.1 FUJIFILM CORPORATION 143
17.1.1 COMPANY SNAPSHOT 143
17.1.2 REVENUE ANALYSIS 143
17.1.3 COMPANY SHARE ANALYSIS 144
17.1.4 PRODUCT PORTFOLIO 144
17.1.5 RECENT DEVELOPMENT 145
17.1.5.1 ACQUISITION 145
17.2 THERMO FISHER SCIENTIFIC INC. 146
17.2.1 COMPANY SNAPSHOT 146
17.2.2 REVENUE ANALYSIS 146
17.2.3 COMPANY SHARE ANALYSIS 147
17.2.4 PRODUCT PORTFOLIO 147
17.2.5 RECENT DEVELOPMENTS 150
17.2.5.1 EVENT 150
17.2.5.2 ACQUISITION 151
17.3 LONZA. 152
17.3.1 COMPANY SNAPSHOT 152
17.3.2 REVENUE ANALYSIS 152
17.3.3 COMPANY SHARE ANALYSIS 153
17.3.4 PRODUCT PORTFOLIO 153
17.3.5 RECENT DEVELOPMENTS 154
17.3.5.1 EXPANSION 154
17.4 MERCK KGAA 155
17.4.1 COMPANY SNAPSHOT 155
17.4.2 REVENUE ANALYSIS 155
17.4.3 COMPANY SHARE ANALYSIS 156
17.4.4 PRODUCT PORTFOLIO 156
17.4.5 RECENT DEVELOPMENT 159
17.4.5.1 AGREEMENT 159
17.5 EVOTEC SE. 160
17.5.1 COMPANY SNAPSHOT 160
17.5.2 REVENUE ANALYSIS 160
17.5.3 COMPANY SHARE ANALYSIS 161
17.5.4 PRODUCT PORTFOLIO 161
17.5.5 RECENT DEVELOPMENTS 161
17.5.5.1 AGREEMENT 161
17.5.5.2 COLLABORATION 162

17.6 APPLIED STEMCELL. 163
17.6.1 COMPANY SNAPSHOT 163
17.6.2 PRODUCT PORTFOLIO 163
17.6.3 RECENT DEVELOPMENTS 169
17.6.3.1 PRODUCT LAUNCH 169
17.7 AXOL BIOSCIENCE LTD. 170
17.7.1 COMPANY SNAPSHOT 170
17.7.2 PRODUCT PORTFOLIO 170
17.7.3 RECENT DEVELOPMENTS 173
17.7.3.1 MERGER 173
17.7.3.2 PRODUCT LAUNCH 174
17.8 CELL APPLICATIONS, INC. 175
17.8.1 COMPANY SNAPSHOT 175
17.8.2 PRODUCT PORTFOLIO 175
17.8.3 RECENT DEVELOPMENT 176
17.8.3.1 PARTNERSHIP 176
17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 177
17.9.1 COMPANY SNAPSHOT 177
17.9.2 REVENUE ANALYSIS 177
17.9.3 PRODUCT PORTFOLIO 178
17.9.4 RECENT DEVELOPMENT 178
17.9.4.1 ACQUISITION 178
17.10 CITIUS PHARMACEUTICALS, INC. 179
17.10.1 COMPANY SNAPSHOT 179
17.10.2 PRODUCT PORTFOLIO 179
17.10.3 RECENT DEVELOPMENT 179
17.10.3.1 AGREEMENT 179
17.11 CORNING INCORPORATED 180
17.11.1 COMPANY SNAPSHOT 180
17.11.2 REVENUE ANALYSIS 180
17.11.3 PRODUCT PORTFOLIO 181
17.11.4 RECENT DEVELOPMENT 181
17.11.4.1 AGREEMENT 181
17.12 FATE THERAPEUTICS 182
17.12.1 COMPANY SNAPSHOT 182
17.12.2 PRODUCT PORTFOLIO 182
17.12.3 RECENT DEVELOPMENT 182
17.12.3.1 CLINICAL TRIAL 182

17.13 GENECOPOEIA, INC. 183
17.13.1 COMPANY SNAPSHOT 183
17.13.2 PRODUCT PORTFOLIO 183
17.13.3 RECENT DEVELOPMENT 183
17.14 HOPSTEM BIOTECHNOLOGY LLC. 184
17.14.1 COMPANY SNAPSHOT 184
17.14.2 PRODUCT PORTFOLIO 184
17.14.3 RECENT DEVELOPMENT 184
17.14.3.1 PARTNERSHIP 184
17.15 HORIZON DISCOVERY LTD. 185
17.15.1 COMPANY SNAPSHOT 185
17.15.2 PRODUCT PORTFOLIO 185
17.15.3 RECENT DEVELOPMENT 185
17.16 LUMACYTE 186
17.16.1 COMPANY SNAPSHOT 186
17.16.2 PRODUCT PORTFOLIO 186
17.16.3 RECENT DEVELOPMENT 187
17.16.3.1 COLLABORATION 187
17.17 R & D SYSTEMS, INC. 188
17.17.1 COMPANY SNAPSHOT 188
17.17.2 REVENUE ANALYSIS 188
17.17.3 PRODUCT PORTFOLIO 189
17.17.4 RECENT DEVELOPMENT 190
17.18 REPROCELL INC. 191
17.18.1 COMPANY SNAPSHOT 191
17.18.2 PRODUCT PORTFOLIO 191
17.18.3 RECENT DEVELOPMENTS 192
17.18.3.1 COLLABORATION 192
17.18.3.2 FACILITY EXPANSION 193
17.18.3.3 SERVICE LAUNCH 193
17.19 TAKARA BIO INC. 194
17.19.1 COMPANY SNAPSHOT 194
17.19.2 REVENUE ANALYSIS 194
17.19.3 PRODUCT PORTFOLIO 195
17.19.4 RECENT DEVELOPMENTS 195
17.19.4.1 NEW FACILITY LAUNCH 195

17.20 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY) 196
17.20.1 COMPANY SNAPSHOT 196
17.20.2 REVENUE ANALYSIS 196
17.20.3 PRODUCT PORTFOLIO 197
17.20.4 RECENT DEVELOPMENT 197
17.20.4.1 ACQUISITION 197
18 QUESTIONNAIRE 198
19 RELATED REPORTS 202